<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333057</url>
  </required_header>
  <id_info>
    <org_study_id>NVU-002 (SEECASE)</org_study_id>
    <nct_id>NCT03333057</nct_id>
  </id_info>
  <brief_title>Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novaliq GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novaliq GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane&#xD;
      (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye&#xD;
      Disease (DED).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Actual">July 27, 2018</completion_date>
  <primary_completion_date type="Actual">May 18, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corneal Fluorescein Staining (CFS) Total (NEI Grading)</measure>
    <time_frame>baseline and 2 months</time_frame>
    <description>The primary efficacy variable was comparison of absolute and change from baseline between treatments for total Corneal Fluorescein Staining (tCFS) according to the National Eye Institute grading (NEI Scale) at week 8&#xD;
The NEI Scale is a standardized grading system. 0-3 is used for each of the five areas on each cornea. Grade 0 will be specified when no staining is present. The maximum total score for each eye is 15. Higher values describe greater staining and corneal damage.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">336</enrollment>
  <condition>Dry Eye Disease (DED)</condition>
  <arm_group>
    <arm_group_label>NOV03 4 times daily (QID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perfluorohexyloctance solution 4 times daily (QID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NOV03 2 times daily (BID)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Perfluorohexyloctance solution 2 times daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 4 times daily (QID)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution (0.9% sodium chloride solution) 4 times daily (QID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2 times daily (BID)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution (0.9% sodium chloride solution) 2 times daily (BID)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOV03</intervention_name>
    <description>Perfluorohexyloctane</description>
    <arm_group_label>NOV03 2 times daily (BID)</arm_group_label>
    <arm_group_label>NOV03 4 times daily (QID)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution (0.9% sodium chloride solution)</description>
    <arm_group_label>Placebo 2 times daily (BID)</arm_group_label>
    <arm_group_label>Placebo 4 times daily (QID)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed ICF (Informed Consent Form)&#xD;
&#xD;
          -  Subject-reported history of Drye Eye Disease (DED) in both eyes&#xD;
&#xD;
          -  Ability and willingness to follow instructions, including participation in all study&#xD;
             assessments and visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, nursing or planning pregnancy&#xD;
&#xD;
          -  Unwillingness to submit a blood pregnancy test at screening and the last visit (or&#xD;
             early termination visit) if of childbearing potential, or unwillingness to use&#xD;
             acceptable means of birth control&#xD;
&#xD;
          -  Clinically significant slit-lamp findings or abnormal lid anatomy at screening&#xD;
&#xD;
          -  Ocular/peri-ocular malignancy&#xD;
&#xD;
          -  History of herpetic keratitis&#xD;
&#xD;
          -  Active ocular allergies or ocular allergies that are expected to be active during the&#xD;
             study&#xD;
&#xD;
          -  Ongoing ocular or systemic infection&#xD;
&#xD;
          -  Wear contact lenses within 1 month prior to screening or anticipated use of contact&#xD;
             lenses during the study&#xD;
&#xD;
          -  Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have&#xD;
             planned ocular and/or lid surgeries over the study period&#xD;
&#xD;
          -  Presence of uncontrolled systemic diseases&#xD;
&#xD;
          -  Presence of known allergy and/or sensitivity to the study drug or saline components&#xD;
&#xD;
          -  Use of any topical steroids treatments, topical cyclosporine, lifitegrast, serum tears&#xD;
             or topical anti-glaucoma medication within 2 months prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonja Kroesser, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Novaliq GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <zip>90701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Lake Villa</city>
        <state>Illinois</state>
        <zip>60046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Pennington</city>
        <state>New Jersey</state>
        <zip>08534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tauber J, Wirta DL, Sall K, Majmudar PA, Willen D, Kr√∂sser S; SEECASE study group. A Randomized Clinical Study (SEECASE) to Assess Efficacy, Safety, and Tolerability of NOV03 for Treatment of Dry Eye Disease. Cornea. 2021 Sep 1;40(9):1132-1140. doi: 10.1097/ICO.0000000000002622.</citation>
    <PMID>33369937</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <results_first_submitted>April 30, 2021</results_first_submitted>
  <results_first_submitted_qc>April 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 24, 2021</results_first_posted>
  <disposition_first_submitted>June 7, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>June 7, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 10, 2019</disposition_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03333057/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NOV03 2 Times Daily (BID)</title>
          <description>Perfluorohexyloctance solution 2 times daily (BID)&#xD;
NOV03: Perfluorohexyloctane</description>
        </group>
        <group group_id="P2">
          <title>NOV03 4 Times Daily (QID)</title>
          <description>Perfluorohexyloctance solution 4 times daily&#xD;
NOV03: Perfluorohexyloctane</description>
        </group>
        <group group_id="P3">
          <title>Placebo BID/QID</title>
          <description>Saline solution (0.9% sodium chloride solution) 2/4 times daily (BID/QID)&#xD;
Placebo: Saline solution (0.9% sodium chloride solution)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NOV03 2 Times Daily (BID)</title>
          <description>Perfluorohexyloctance solution 2 times daily (BID)&#xD;
NOV03: Perfluorohexyloctane</description>
        </group>
        <group group_id="B2">
          <title>NOV03 4 Times Daily (QID)</title>
          <description>Perfluorohexyloctance solution 4 times daily&#xD;
NOV03: Perfluorohexyloctane</description>
        </group>
        <group group_id="B3">
          <title>Placebo BID/QID</title>
          <description>Saline solution (0.9% sodium chloride solution) 2/4 times daily (BID/QID)&#xD;
Placebo: Saline solution (0.9% sodium chloride solution)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="111"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="111"/>
            <count group_id="B4" value="336"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" lower_limit="22" upper_limit="86"/>
                    <measurement group_id="B2" value="53.0" lower_limit="22" upper_limit="86"/>
                    <measurement group_id="B3" value="53.8" lower_limit="19" upper_limit="85"/>
                    <measurement group_id="B4" value="53.6" lower_limit="19" upper_limit="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="239"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Corneal Fluorescein Staining (CFS) Total (NEI Grading)</title>
        <description>The primary efficacy variable was comparison of absolute and change from baseline between treatments for total Corneal Fluorescein Staining (tCFS) according to the National Eye Institute grading (NEI Scale) at week 8&#xD;
The NEI Scale is a standardized grading system. 0-3 is used for each of the five areas on each cornea. Grade 0 will be specified when no staining is present. The maximum total score for each eye is 15. Higher values describe greater staining and corneal damage.</description>
        <time_frame>baseline and 2 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NOV03 2 Times Daily (BID)</title>
            <description>Perfluorohexyloctance solution 2 times daily (BID)&#xD;
NOV03: Perfluorohexyloctane</description>
          </group>
          <group group_id="O2">
            <title>NOV03 4 Times Daily (QID)</title>
            <description>Perfluorohexyloctance solution 4 times daily&#xD;
NOV03:Perfluorohexyloctane</description>
          </group>
          <group group_id="O3">
            <title>Placebo BID/QID</title>
            <description>Saline solution (0.9% sodium chloride solution) 2/4 times daily (BID/QID)&#xD;
Placebo: Saline solution (0.9% sodium chloride solution)</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Fluorescein Staining (CFS) Total (NEI Grading)</title>
          <description>The primary efficacy variable was comparison of absolute and change from baseline between treatments for total Corneal Fluorescein Staining (tCFS) according to the National Eye Institute grading (NEI Scale) at week 8&#xD;
The NEI Scale is a standardized grading system. 0-3 is used for each of the five areas on each cornea. Grade 0 will be specified when no staining is present. The maximum total score for each eye is 15. Higher values describe greater staining and corneal damage.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" lower_limit="-2.27" upper_limit="-1.30"/>
                    <measurement group_id="O2" value="-2.11" lower_limit="-2.59" upper_limit="-1.63"/>
                    <measurement group_id="O3" value="-0.93" lower_limit="-1.41" upper_limit="-0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>whole study duration (8 weeks per patient)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NOV03 2 Times Daily (BID)</title>
          <description>Perfluorohexyloctance solution 2 times daily (BID)&#xD;
NOV03: Perfluorohexyloctane</description>
        </group>
        <group group_id="E2">
          <title>NOV03 4 Times Daily (QID)</title>
          <description>Perfluorohexyloctance solution 4 times daily&#xD;
NOV03: Perfluorohexyloctane</description>
        </group>
        <group group_id="E3">
          <title>Placebo BID/QID</title>
          <description>Saline solution (0.9% sodium chloride solution) 2/4 times daily (BID/QID)&#xD;
Placebo: Saline solution (0.9% sodium chloride solution)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Instillation site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Instillation site irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sonja Kroesser</name_or_title>
      <organization>Novaliq GmbH</organization>
      <phone>+49 6221 50259 ext 0</phone>
      <email>info@novaliq.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

